Cargando…
AXL-Receptor Targeted 14FN3 Based Single Domain Proteins (Pronectins™) from 3 Synthetic Human Libraries as Components for Exploring Novel Bispecific Constructs against Solid Tumors
A highly specific AXL-receptor targeted family of non-immunoglobulin, single domain protein binders (Pronectins™) have been isolated from three (3) synthetic libraries that employ the human scaffold of the 14th domain of Fibronectin III (14FN3) and evolutionary CDRs diversity of over 25 billion loop...
Autores principales: | Hokanson, Craig A., Zacco, Emanuela, Cappuccilli, Guido, Odineca, Tatjana, Crea, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775294/ https://www.ncbi.nlm.nih.gov/pubmed/36551940 http://dx.doi.org/10.3390/biomedicines10123184 |
Ejemplares similares
-
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer
por: Riillo, Caterina, et al.
Publicado: (2023) -
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas
por: Polerà, Nicoletta, et al.
Publicado: (2023) -
TWEAK and Fn14 in the Neurovascular Unit
por: Yepes, Manuel
Publicado: (2013) -
Fn14 exacerbates acute lung injury by activating the NLRP3 inflammasome in mice
por: Guan, Xin-Xin, et al.
Publicado: (2022) -
The TWEAK Receptor Fn14 is a Novel Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment
por: Zhou, Hong, et al.
Publicado: (2012)